Reliable Data You Can Trust
Reliable Data You Can Trust
A recent report published by Infinium Global Research on the radiodermatitis market provides an in-depth analysis of segments and sub-segments in the global as well as regional radiodermatitis market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional radiodermatitis market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of the global radiodermatitis market. According to the report, the global radiodermatitis market is projected to grow at a CAGR of 4.43% over the forecast period of 2021-2027.
The radiodermatitis market was valued at USD 363 million in 2021 and is expected to reach USD 471 million in 2027, with a CAGR of 4.43% during the forecast period. Radiodermatitis, also known as radiation dermatitis, is the skin condition observed in patients undergoing radiation therapy used to treat cancer and other health conditions. Radiodermatitis can be both an acute or chronic disease with itching, redness, soreness, flaking, peeling, blisters, and others. Furthermore, this disease can be categorized into four grades of severity: redness, peeling, swelling, and death of skin cells, which can be very painful for cancer patients. Moreover, many medicines and ointments are available for radiodermatitis treatment, like hydrogel, silver lea, and other dressings. Additionally, almost 95 percent of the patients who received radiation for cancer treatment are affected by radiodermatitis, and around 85 percent of the patients have a moderate-to-severe cutaneous condition. It has been estimated that, in many developed countries, nearly half of the patients who receive treatment for cancer were also subjected to radiation therapy, and about all of them experience some degree of skin reaction.
The factors like surging cases of cancer around the globe and the increasing adoption of radiotherapy among people are projected to propel the growth of the radiodermatitis market during the forecast period. Furthermore, a rising number of public and private healthcare organizations consistently try to promote awareness about radiodermatitis management and treatment. This is the prime factor driving the growth of the radiodermatitis market. Moreover, the number of clinical studies conducted to evaluate the efficacy of a wide array of radiodermatitis treatment products for treatment is rising, due to which the product pipeline is expected to expand, which can boost the market’s growth. However, the people of underdeveloped countries lack information exposure about acute or chronic radiodermatitis, which is expected to hamper the development of the market during the forecast period. On the other hand, the peoples of developed countries have growing awareness about enhancing their quality of life and enormous expansion of healthcare establishments across the globe, which is expected to create outstanding opportunities for the market’s growth during the forecast period.
The Asia Pacific is the region that captured the dominant share of the market and currently dominating the market. The critical contributor to the substantial share captured by this region is the expanding cancer patient base present across the region. Additionally, key players of these regions collaborate to increase their product portfolio expansion capabilities. This is also one of the critical reasons for the market’s growth in the area. Moreover, many well-established pharmaceutical companies in the Asia Pacific region are extensively involved in the commercialization of their products and promoting their usage amongst the end-users. Also, the research activities, favorable government, and an increase in outsourcing by developed economies are other factors propelling the market’s growth in the region. After the Asia Pacific, North America held the second-largest share of the radiodermatitis market due to high R&D investments deployed by global players and their focus on attaining a competitive position. Additionally, sophisticated healthcare infrastructure and high disposable income of the people are creating significant growth opportunities in the North American region.
The report on the global radiodermatitis market covers segments such as product, route of administration, and distribution channels. On the basis of product, the sub-markets include hydrophilic creams, antibiotics, dressings, hydrogel & hydrocolloid, corticosteroids, silicone coated, and no sting barrier film. On the basis of route of administration, the sub-markets include topical, and oral. On the basis of distribution channels, the sub-markets include hospitals, cancer specialty clinics, research institutes, and others.
The report provides profiles of the companies in the market such as 3M Company, Mölnlycke, HARTMANN, KeraNetics, Inc, Smith & Nephew Plc, Charles River Laboratories, The Jackson Laboratory, Stratpharma, InterMed S.A, and AceTech.
The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of radiodermatitis market. Moreover, the study highlights current market trends and provides forecast from 2021-2027. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.
Please Choose One of them.